Baseline characteristics of patients with and without fatty liver
| Characteristics | All | Fatty liver | No fatty liver | p Value |
| n | 612 | 356 | 256 | |
| Age (years) | 63±11 | 63±10 | 63±12 | 0.61 |
| Male gender, n (%) | 433 (70.8) | 264 (74.2) | 169 (66.0) | 0.029 |
| Smoking, n (%) | 0.23 | |||
| Current smoker | 194 (31.7) | 122 (34.3) | 72 (28.1) | |
| Ex-smoker | 115 (18.8) | 67 (18.8) | 48 (18.8) | |
| Non-smoker | 303 (49.5) | 167 (46.9) | 136 (53.1) | |
| Alcohol, n (%) | 0.84 | |||
| Current drinker | 93 (15.2) | 54 (15.2) | 39 (15.2) | |
| Ex-drinker | 30 (4.9) | 19 (5.3) | 11 (4.3) | |
| Non-drinker | 489 (79.9) | 283 (79.5) | 206 (80.5) | |
| Diabetes, n (%) | 191 (31.2) | 147 (41.3) | 44 (17.2) | <0.001 |
| Hypertension, n (%) | 401 (65.5) | 252 (70.8) | 149 (58.2) | 0.001 |
| Systolic blood pressure (mm Hg) | 137±22 | 140±22 | 132±21 | <0.001 |
| Diastolic blood pressure (mm Hg) | 75±13 | 77±13 | 72±13 | <0.001 |
| Body mass index (kg/m2) | 24.7±3.9 | 25.7±4.0 | 23.2±3.1 | <0.001 |
| Male | 24.3±3.3 | 25.2±3.4 | 23.0±2.8 | <0.001 |
| Female | 25.5±4.9 | 27.2±5.2 | 23.6±3.7 | <0.001 |
| Waist circumference (cm) | 90±9 | 93±8 | 87±9 | <0.001 |
| Male | 91±8 | 93±8 | 88±8 | <0.001 |
| Female | 89±11 | 93±9 | 84±10 | <0.001 |
| Fasting glucose (mmol/l) | 6.2±2.1 | 6.4±2.2 | 6.0±2.0 | 0.021 |
| Total cholesterol (mmol/l) | 4.5±1.2 | 4.5±1.3 | 4.5±1.1 | 0.66 |
| HDL-cholesterol (mmol/l) | 1.2±0.3 | 1.1±0.3 | 1.2±0.4 | <0.001 |
| LDL-cholesterol (mmol/l) | 2.6±0.9 | 2.6±0.9 | 2.6±0.9 | 0.50 |
| Triglycerides (mmol/l) | 1.4 (1.0, 1.9) | 1.4 (1.0, 2.1) | 1.2 (0.9, 1.8) | 0.001 |
| Creatinine (μmol/l) | 89 (76, 105) | 91 (78, 107) | 87 (74, 104) | 0.033 |
| Alanine aminotransferase (IU/l) | 26 (19, 40) | 28 (19, 44) | 24 (18, 38) | 0.052 |
| Drugs, n (%) | ||||
| Aspirin | 523 (85.5) | 323 (90.7) | 200 (78.1) | <0.001 |
| Clopidogrel | 377 (61.6) | 242 (68.0) | 135 (52.7) | <0.001 |
| β-Blockers | 423 (69.1) | 267 (75.0) | 156 (60.9) | <0.001 |
| Calcium channel blockers | 133 (21.7) | 87 (24.4) | 46 (18.0) | 0.056 |
| ACE inhibitors | 310 (50.7) | 192 (53.9) | 118 (46.1) | 0.056 |
| Angiotensin receptor antagonists | 32 (5.2) | 20 (5.6) | 12 (4.7) | 0.61 |
| Statins | 399 (65.2) | 252 (70.8) | 147 (57.4) | 0.001 |
| Metformin | 77 (12.6) | 62 (17.4) | 15 (5.9) | <0.001 |
| Thiazolidinedione | 13 (2.1) | 10 (2.8) | 3 (1.2) | 0.26 |
| Sulfonylurea | 111 (18.1) | 83 (23.3) | 28 (10.9) | <0.001 |
| Insulin | 25 (4.1) | 19 (5.3) | 6 (2.3) | 0.065 |
| Indication of coronary angiogram, n (%) | <0.001 | |||
| Acute coronary syndrome or myocardial infarction | 279 (45.6) | 167 (46.9) | 112 (43.8) | |
| Stable angina | 273 (44.6) | 173 (48.6) | 100 (39.1) | |
| Valvular heart disease | 46 (7.5) | 10 (2.8) | 36 (14.1) | |
| Others | 14 (2.3) | 6 (1.7) | 8 (3.1) | |
| Follow-up duration (weeks) | 87±22 | 89±19 | 85±25 | 0.055 |
Continuous variables were expressed as mean±SD or median (IQR).
ACE, angiotensin-converting enzyme; HDL, high-density lipoprotein; LDL, low-density lipoprotein.